Editing the Central Nervous System Through CRISPR/Cas9 Systems

The translational gap to treatments based on gene therapy has been reduced in recent years because of improvements in gene editing tools, such as the CRISPR/Cas9 system and its variations. This has allowed the development of more precise therapies for neurodegenerative diseases, where access is priv...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in molecular neuroscience 2019-05, Vol.12, p.110-110
Main Authors: Cota-Coronado, Agustin, Díaz-Martínez, Néstor Fabián, Padilla-Camberos, Eduardo, Díaz-Martínez, N Emmanuel
Format: Article
Language:English
Subjects:
adenovirus-associated virus
Alzheimer's disease
Blood-brain barrier
Brain research
Central nervous system
CRISPR
CRISPR/Cas9
d-Cas9
Deoxyribonucleic acid
Design
Disease
DNA
Efficiency
Enzymes
Gene therapy
Genomes
Mutation
Nanoparticles
Neurodegeneration
Neurodegenerative diseases
Neuroscience
“Trojan horse” peptides
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c490t-514e15dd4602099d072aefe77542433cca4d0b9c8b160c564556dce1e805030d3
cites cdi_FETCH-LOGICAL-c490t-514e15dd4602099d072aefe77542433cca4d0b9c8b160c564556dce1e805030d3
container_end_page 110
container_issue
container_start_page 110
container_title Frontiers in molecular neuroscience
container_volume 12
creator Cota-Coronado, Agustin
Díaz-Martínez, Néstor Fabián
Padilla-Camberos, Eduardo
Díaz-Martínez, N Emmanuel
description The translational gap to treatments based on gene therapy has been reduced in recent years because of improvements in gene editing tools, such as the CRISPR/Cas9 system and its variations. This has allowed the development of more precise therapies for neurodegenerative diseases, where access is privileged. As a result, engineering of complexes that can access the central nervous system (CNS) with the least potential inconvenience is fundamental. In this review article, we describe current alternatives to generate systems based on CRISPR/Cas9 that can cross the blood-brain barrier (BBB) and may be used further clinically to improve treatment for neurodegeneration in Parkinson's and Alzheimer's disease (AD).
doi_str_mv 10.3389/fnmol.2019.00110
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_20ae13a3662c433e922648ce097475f7</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_20ae13a3662c433e922648ce097475f7</doaj_id><sourcerecordid>2340041728</sourcerecordid><originalsourceid>FETCH-LOGICAL-c490t-514e15dd4602099d072aefe77542433cca4d0b9c8b160c564556dce1e805030d3</originalsourceid><addsrcrecordid>eNpdkc1P3DAQxa2qqFDovacqUi9cdhl_Jr4goQjalVBBQM-W15nsZpXEYCdI_Pc4u1sEPdnyvPn5zTxCvlOYc17os7rvfDtnQPUcgFL4RI6oUmwmQevP7-6H5GuMGwDFlORfyCGnVFMm6BE5v6yaoelX2bDGrMR-CLbN_mB49mPM7l_igF32sA5-XK2z8m5xf3t3Vtqo96V4Qg5q20b8tj-Pyd-ry4fy9-z65teivLieOaFhmEkqkMqqEgpYslNBzizWmOdSMMG5c1ZUsNSuWFIFTiohpaocUixAAoeKH5PFjlt5uzGPoelseDHeNmb74MPK2DA0rkXDwCLllqfZXWKjZkyJwiHoXOSyzhPrfMd6HJcdpm-2Q3-Afqz0zdqs_LNRcvI_AU73gOCfRoyD6ZrosG1tj2lthnEBIGjOiiT9-Z9048fQp1UlFWjJUgyTCnYqF3yMAes3MxTMFLTZBm2moM026NTy4_0Qbw3_kuWvQ_-h6Q</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2309529128</pqid></control><display><type>article</type><title>Editing the Central Nervous System Through CRISPR/Cas9 Systems</title><source>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</source><source>PubMed Central</source><creator>Cota-Coronado, Agustin ; Díaz-Martínez, Néstor Fabián ; Padilla-Camberos, Eduardo ; Díaz-Martínez, N Emmanuel</creator><creatorcontrib>Cota-Coronado, Agustin ; Díaz-Martínez, Néstor Fabián ; Padilla-Camberos, Eduardo ; Díaz-Martínez, N Emmanuel</creatorcontrib><description>The translational gap to treatments based on gene therapy has been reduced in recent years because of improvements in gene editing tools, such as the CRISPR/Cas9 system and its variations. This has allowed the development of more precise therapies for neurodegenerative diseases, where access is privileged. As a result, engineering of complexes that can access the central nervous system (CNS) with the least potential inconvenience is fundamental. In this review article, we describe current alternatives to generate systems based on CRISPR/Cas9 that can cross the blood-brain barrier (BBB) and may be used further clinically to improve treatment for neurodegeneration in Parkinson's and Alzheimer's disease (AD).</description><identifier>ISSN: 1662-5099</identifier><identifier>EISSN: 1662-5099</identifier><identifier>DOI: 10.3389/fnmol.2019.00110</identifier><identifier>PMID: 31191241</identifier><language>eng</language><publisher>Switzerland: Frontiers Research Foundation</publisher><subject>adenovirus-associated virus ; Alzheimer's disease ; Blood-brain barrier ; Brain research ; Central nervous system ; CRISPR ; CRISPR/Cas9 ; d-Cas9 ; Deoxyribonucleic acid ; Design ; Disease ; DNA ; Efficiency ; Enzymes ; Gene therapy ; Genomes ; Mutation ; Nanoparticles ; Neurodegeneration ; Neurodegenerative diseases ; Neuroscience ; “Trojan horse” peptides</subject><ispartof>Frontiers in molecular neuroscience, 2019-05, Vol.12, p.110-110</ispartof><rights>2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright © 2019 Cota-Coronado, Díaz-Martínez, Padilla-Camberos and Díaz-Martínez. 2019 Cota-Coronado, Díaz-Martínez, Padilla-Camberos and Díaz-Martínez</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c490t-514e15dd4602099d072aefe77542433cca4d0b9c8b160c564556dce1e805030d3</citedby><cites>FETCH-LOGICAL-c490t-514e15dd4602099d072aefe77542433cca4d0b9c8b160c564556dce1e805030d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2309529128/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2309529128?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25752,27923,27924,37011,37012,44589,53790,53792,74997</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31191241$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cota-Coronado, Agustin</creatorcontrib><creatorcontrib>Díaz-Martínez, Néstor Fabián</creatorcontrib><creatorcontrib>Padilla-Camberos, Eduardo</creatorcontrib><creatorcontrib>Díaz-Martínez, N Emmanuel</creatorcontrib><title>Editing the Central Nervous System Through CRISPR/Cas9 Systems</title><title>Frontiers in molecular neuroscience</title><addtitle>Front Mol Neurosci</addtitle><description>The translational gap to treatments based on gene therapy has been reduced in recent years because of improvements in gene editing tools, such as the CRISPR/Cas9 system and its variations. This has allowed the development of more precise therapies for neurodegenerative diseases, where access is privileged. As a result, engineering of complexes that can access the central nervous system (CNS) with the least potential inconvenience is fundamental. In this review article, we describe current alternatives to generate systems based on CRISPR/Cas9 that can cross the blood-brain barrier (BBB) and may be used further clinically to improve treatment for neurodegeneration in Parkinson's and Alzheimer's disease (AD).</description><subject>adenovirus-associated virus</subject><subject>Alzheimer's disease</subject><subject>Blood-brain barrier</subject><subject>Brain research</subject><subject>Central nervous system</subject><subject>CRISPR</subject><subject>CRISPR/Cas9</subject><subject>d-Cas9</subject><subject>Deoxyribonucleic acid</subject><subject>Design</subject><subject>Disease</subject><subject>DNA</subject><subject>Efficiency</subject><subject>Enzymes</subject><subject>Gene therapy</subject><subject>Genomes</subject><subject>Mutation</subject><subject>Nanoparticles</subject><subject>Neurodegeneration</subject><subject>Neurodegenerative diseases</subject><subject>Neuroscience</subject><subject>“Trojan horse” peptides</subject><issn>1662-5099</issn><issn>1662-5099</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpdkc1P3DAQxa2qqFDovacqUi9cdhl_Jr4goQjalVBBQM-W15nsZpXEYCdI_Pc4u1sEPdnyvPn5zTxCvlOYc17os7rvfDtnQPUcgFL4RI6oUmwmQevP7-6H5GuMGwDFlORfyCGnVFMm6BE5v6yaoelX2bDGrMR-CLbN_mB49mPM7l_igF32sA5-XK2z8m5xf3t3Vtqo96V4Qg5q20b8tj-Pyd-ry4fy9-z65teivLieOaFhmEkqkMqqEgpYslNBzizWmOdSMMG5c1ZUsNSuWFIFTiohpaocUixAAoeKH5PFjlt5uzGPoelseDHeNmb74MPK2DA0rkXDwCLllqfZXWKjZkyJwiHoXOSyzhPrfMd6HJcdpm-2Q3-Afqz0zdqs_LNRcvI_AU73gOCfRoyD6ZrosG1tj2lthnEBIGjOiiT9-Z9048fQp1UlFWjJUgyTCnYqF3yMAes3MxTMFLTZBm2moM026NTy4_0Qbw3_kuWvQ_-h6Q</recordid><startdate>20190527</startdate><enddate>20190527</enddate><creator>Cota-Coronado, Agustin</creator><creator>Díaz-Martínez, Néstor Fabián</creator><creator>Padilla-Camberos, Eduardo</creator><creator>Díaz-Martínez, N Emmanuel</creator><general>Frontiers Research Foundation</general><general>Frontiers Media S.A</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7XB</scope><scope>88I</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2P</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20190527</creationdate><title>Editing the Central Nervous System Through CRISPR/Cas9 Systems</title><author>Cota-Coronado, Agustin ; Díaz-Martínez, Néstor Fabián ; Padilla-Camberos, Eduardo ; Díaz-Martínez, N Emmanuel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c490t-514e15dd4602099d072aefe77542433cca4d0b9c8b160c564556dce1e805030d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>adenovirus-associated virus</topic><topic>Alzheimer's disease</topic><topic>Blood-brain barrier</topic><topic>Brain research</topic><topic>Central nervous system</topic><topic>CRISPR</topic><topic>CRISPR/Cas9</topic><topic>d-Cas9</topic><topic>Deoxyribonucleic acid</topic><topic>Design</topic><topic>Disease</topic><topic>DNA</topic><topic>Efficiency</topic><topic>Enzymes</topic><topic>Gene therapy</topic><topic>Genomes</topic><topic>Mutation</topic><topic>Nanoparticles</topic><topic>Neurodegeneration</topic><topic>Neurodegenerative diseases</topic><topic>Neuroscience</topic><topic>“Trojan horse” peptides</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cota-Coronado, Agustin</creatorcontrib><creatorcontrib>Díaz-Martínez, Néstor Fabián</creatorcontrib><creatorcontrib>Padilla-Camberos, Eduardo</creatorcontrib><creatorcontrib>Díaz-Martínez, N Emmanuel</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>Biological Sciences</collection><collection>ProQuest Science Journals</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ (Directory of Open Access Journals)</collection><jtitle>Frontiers in molecular neuroscience</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cota-Coronado, Agustin</au><au>Díaz-Martínez, Néstor Fabián</au><au>Padilla-Camberos, Eduardo</au><au>Díaz-Martínez, N Emmanuel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Editing the Central Nervous System Through CRISPR/Cas9 Systems</atitle><jtitle>Frontiers in molecular neuroscience</jtitle><addtitle>Front Mol Neurosci</addtitle><date>2019-05-27</date><risdate>2019</risdate><volume>12</volume><spage>110</spage><epage>110</epage><pages>110-110</pages><issn>1662-5099</issn><eissn>1662-5099</eissn><abstract>The translational gap to treatments based on gene therapy has been reduced in recent years because of improvements in gene editing tools, such as the CRISPR/Cas9 system and its variations. This has allowed the development of more precise therapies for neurodegenerative diseases, where access is privileged. As a result, engineering of complexes that can access the central nervous system (CNS) with the least potential inconvenience is fundamental. In this review article, we describe current alternatives to generate systems based on CRISPR/Cas9 that can cross the blood-brain barrier (BBB) and may be used further clinically to improve treatment for neurodegeneration in Parkinson's and Alzheimer's disease (AD).</abstract><cop>Switzerland</cop><pub>Frontiers Research Foundation</pub><pmid>31191241</pmid><doi>10.3389/fnmol.2019.00110</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1662-5099
ispartof Frontiers in molecular neuroscience, 2019-05, Vol.12, p.110-110
issn 1662-5099
1662-5099
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_20ae13a3662c433e922648ce097475f7
source Publicly Available Content Database (Proquest) (PQ_SDU_P3); PubMed Central
subjects adenovirus-associated virus
Alzheimer's disease
Blood-brain barrier
Brain research
Central nervous system
CRISPR
CRISPR/Cas9
d-Cas9
Deoxyribonucleic acid
Design
Disease
DNA
Efficiency
Enzymes
Gene therapy
Genomes
Mutation
Nanoparticles
Neurodegeneration
Neurodegenerative diseases
Neuroscience
“Trojan horse” peptides
title Editing the Central Nervous System Through CRISPR/Cas9 Systems
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T21%3A19%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Editing%20the%20Central%20Nervous%20System%20Through%20CRISPR/Cas9%20Systems&rft.jtitle=Frontiers%20in%20molecular%20neuroscience&rft.au=Cota-Coronado,%20Agustin&rft.date=2019-05-27&rft.volume=12&rft.spage=110&rft.epage=110&rft.pages=110-110&rft.issn=1662-5099&rft.eissn=1662-5099&rft_id=info:doi/10.3389/fnmol.2019.00110&rft_dat=%3Cproquest_doaj_%3E2340041728%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c490t-514e15dd4602099d072aefe77542433cca4d0b9c8b160c564556dce1e805030d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2309529128&rft_id=info:pmid/31191241&rfr_iscdi=true